Skip to content
Homepage
Author:
Artiva Biotherapeutics, Inc.
Posted Date:
June 23, 2026
Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
Artiva Biotherapeutics, Inc.
June 23, 2026
Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today
Artiva Biotherapeutics, Inc.
June 8, 2026
Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
Artiva Biotherapeutics, Inc.
May 28, 2026
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases
Artiva Biotherapeutics, Inc.
May 19, 2026
Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development
Artiva Biotherapeutics, Inc.
May 19, 2026
Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Artiva Biotherapeutics, Inc.
May 8, 2026
Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026
Artiva Biotherapeutics, Inc.
May 8, 2026
Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
Artiva Biotherapeutics, Inc.
May 8, 2026
Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference
Artiva Biotherapeutics, Inc.
April 8, 2026
Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights
Artiva Biotherapeutics, Inc.
March 10, 2026
1
2
Next
